However, approximately primary resistance invariably emerged in 20% of CML patients to imatinib and 30% of EGFR-mutated NSCLC patients to EGFR-TKI therapy4, 5, 6, revealing that personalized difference in genetic background might influence treatment efficacy of TKI in cancer patients. Here, EGFR is linked to non-small cell lung carcinoma.